DK2314315T3 - Blokerende monoklonalt antistof for det humane alfa1-I-domæne af VLA-1 samt dettes anvendelse til behandling af inflammatoriske sygdomme - Google Patents

Blokerende monoklonalt antistof for det humane alfa1-I-domæne af VLA-1 samt dettes anvendelse til behandling af inflammatoriske sygdomme Download PDF

Info

Publication number
DK2314315T3
DK2314315T3 DK10185467.7T DK10185467T DK2314315T3 DK 2314315 T3 DK2314315 T3 DK 2314315T3 DK 10185467 T DK10185467 T DK 10185467T DK 2314315 T3 DK2314315 T3 DK 2314315T3
Authority
DK
Denmark
Prior art keywords
antibody
antigen
binding fragment
human
day
Prior art date
Application number
DK10185467.7T
Other languages
English (en)
Inventor
Fougerolles Antonin De
Philip Gotwals
Roy R Lobb
Victor E Koteliansky
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK2314315T3 publication Critical patent/DK2314315T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Claims (19)

1. Antistof eller antigenbindende fragment deraf, som er i stand til at binde en epitop af VLA-1 omfattende aminosyrerester Val-GIn-Arg-Gly-Gly-Arg (SEQ ID NO: 8), hvor 5 antistoffet eller det antigenbindende fragment deraf er i stand til at binde et humant a1-l-domæne men ikke et rotte a1-l-domæne, til anvendelse ved behandling af en inflammatorisk sygdom i et subjekt.
2. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse 10 med krav 1, hvor epitopen består af aminosyrerester Val-GIn-Arg-Gly-Gly-Arg (SEQ ID NO: 8).
3. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med krav 1 eller 2, hvor den inflammatoriske sygdom er en arthritis eller en vaskulær 15 sygdom.
4. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med ethvert af kravene 1 til 3, hvor den inflammatoriske sygdom er arthritis rheumatoides. 20
5. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med ethvert af kravene 1 til 3, hvor den inflammatoriske sygdom er osteoarthritis, atherosclerose, inflammatorisk tarmsygdom, Crohn's sygdom, gastritis, colitis ulcerosa, periartritis nodosa, betændelse i skjoldbruskkirtlen, aplastisk anæmi, 25 Hodgkin's syge, type I diabetes, alvorlig amyosteni, sarcoidose, nephritisk syndrom, myocardial iskæmi, allergisk næsekatar, respiratorisk besværsyndrom, endotoxin-choksyndrom, psoriasis, eksem, en forbrænding, dermatitis, astma, bronkitis, menstruationskramper, tendinitis, bursitis, smerte, hovedpine, feber eller rheumatisk feber. 30
6. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med krav 1 til 5, hvor antistoffet eller det antigenbindende fragment deraf er et mono-klonalt, polyklonalt, humant, humaniseret eller kimærisk antistof eller antigenbindende fragment deraf. 35
7. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med ethvert af kravene 1 til 6, hvor antistoffet eller det antigenbindende fragment deraf er monoklonalt.
8. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med ethvert af kravene 1 til 7, hvor antistoffet eller det antigenbindende fragment deraf er humaniseret.
9. Antigenbindende fragment til anvendelse i overensstemmelse med ethvert af 10 kravene 1 til 8, hvor det antigenbindende fragment er et Fab, Fab', F(ab')2, eller F(v) fragment.
10. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med ethvert af kravene 1 til 9, hvor subjektet er et menneske. 15
11. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med kravene 1 til 10, hvor antistoffet eller det antigenbindende fragment deraf er til parenteral indgivelse.
12. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med ethvert af kravene 1 til 10, hvor antistoffet eller det antigenbindende fragment deraf er til indgivelse oralt, subkutant, intravenøst, intramuskulært, intraartikulært, intrasynovialt, intrasternalt, intrathecalt, intrahepatisk, intralæsionalt, intrakranielt, nasalt eller topisk. 25
13. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med krav 1 til 12, hvor antistoffet eller det antigenbindende fragment deraf er til indgivelse til subjektet i en mængde fra 0,1 mg/kg/dag til 50 mg/kg/dag, fra 0,1 mg/kg/dag til 20 mg/kg/dag, fra 0,1 mg/kg/dag til 10 mg/kg/dag, fra 0,3 mg/kg/dag til 1 30 mg/kg/dag eller fra 5 mg/kg/dag til 12,5 mg/kg/dag.
14. Antistof eller antigenbindende fragment deraf til anvendelse i overensstemmelse med kravene 1 til 13, hvor antistoffet eller det antigenbindende fragment deraf er til indgivelse til subjektet med intervaller på hver dag til hver fjortende dag. 35
15. Antistof eller antigenbindende fragment deraf, som er i stand til at binde en epitop af VLA-1 omfattende aminosyrerester Val-GIn-Arg-Gly-Gly-Arg (SEQ ID NO: 8), hvor antistoffet eller det antigenbindende fragment deraf er i stand til at binde et humant a1-l-domæne men ikke et rotte a1-l-domæne.
16. Antistof eller antigenbindende fragment deraf ifølge krav 15, hvor epitopen af antistoffet eller det antigenbindende fragment deraf består af aminosyreresterne Val-GIn-Arg-Gly-Gly-Arg (SEQ ID NO: 8).
17. Antistof eller antigenbindende fragment deraf i overensstemmelse med krav 15 eller krav 16 til anvendelse ved behandling af et menneske.
18. Farmaceutisk sammensætning omfattende antistoffet eller det antigenbindende fragment deraf som angivet i et vilkårligt af kravene 1 til 14 eller i overensstemmelse med krav 15 eller krav 16, og en farmaceutisk acceptabel bærer.
19. Antistof eller antigenbindende fragment deraf, som er i stand til at binde til en epitop af VLA-1, hvor antistoffet eller det antigenbindende fragment deraf (i) binder til en kationafhængig epitop af VLA-1, (ii) er i stand til at binde til et humant a1-l-domæne men er ikke i stand til at binde til et rotte a1-l-domæne, og (iii) er i stand til at binde til et RAH a1-l-domæne, som er et rotte a1-l-domæne, hvori rotteresiduer G91, R92, Q93 og L96 er udskiftede med residuer V,Q, R hhv. R.
DK10185467.7T 1999-06-01 2000-06-01 Blokerende monoklonalt antistof for det humane alfa1-I-domæne af VLA-1 samt dettes anvendelse til behandling af inflammatoriske sygdomme DK2314315T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13703899P 1999-06-01 1999-06-01
US18533600P 2000-02-29 2000-02-29
EP04018151.3A EP1488806B1 (en) 1999-06-01 2000-06-01 A blocking monoclonal antibody to VLA-1 and its use for the treatment of vascular disorders

Publications (1)

Publication Number Publication Date
DK2314315T3 true DK2314315T3 (da) 2015-02-02

Family

ID=26834850

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10185467.7T DK2314315T3 (da) 1999-06-01 2000-06-01 Blokerende monoklonalt antistof for det humane alfa1-I-domæne af VLA-1 samt dettes anvendelse til behandling af inflammatoriske sygdomme
DK04018151.3T DK1488806T3 (da) 1999-06-01 2000-06-01 Blokerende monoklonalt antistof mod VLA-1 og dettes anvendelse til behandling af vaskulære lidelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04018151.3T DK1488806T3 (da) 1999-06-01 2000-06-01 Blokerende monoklonalt antistof mod VLA-1 og dettes anvendelse til behandling af vaskulære lidelser

Country Status (28)

Country Link
US (5) US6955810B2 (da)
EP (3) EP1181054A1 (da)
JP (6) JP4817503B2 (da)
CN (1) CN1309419C (da)
AU (2) AU783989B2 (da)
BG (1) BG65579B1 (da)
BR (1) BR0011250A (da)
CA (1) CA2375827C (da)
CY (1) CY1116042T1 (da)
CZ (1) CZ300710B6 (da)
DK (2) DK2314315T3 (da)
EA (1) EA011384B1 (da)
EE (1) EE200100651A (da)
ES (2) ES2557768T3 (da)
GE (1) GEP20063774B (da)
HK (2) HK1043320A1 (da)
HU (1) HUP0202568A3 (da)
IL (2) IL146508A0 (da)
IS (1) IS6179A (da)
MX (1) MXPA01012388A (da)
NO (1) NO20015864L (da)
NZ (1) NZ515686A (da)
PT (2) PT2314315E (da)
SI (2) SI1488806T1 (da)
SK (1) SK17232001A3 (da)
TR (1) TR200103432T2 (da)
WO (1) WO2000072881A1 (da)
YU (1) YU85501A (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011384B1 (ru) 1999-06-01 2009-02-27 Байоджен Айдек Ма Инк. Способ лечения воспалительного заболевания
YU80903A (sh) 2001-04-13 2006-05-25 Biogen Inc. Antitela vla-1
AU2003215298A1 (en) * 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
BR0315054A (pt) * 2002-11-01 2005-08-16 Boys Town Nat Res Hospital Ligando induzìvel para a integrina alfa 1 beta 1 e empregos
WO2005004800A2 (en) * 2003-06-20 2005-01-20 Morehouse School Of Medicine Trypanosome derived apoptotic factors (taf)
WO2005057755A1 (en) * 2003-12-09 2005-06-23 Electrotechnologies Selem, Inc. Polyphase claw-pole machines with a segmented magnetic circuit
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) * 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US10119979B2 (en) * 2006-05-25 2018-11-06 Biogen Ma Inc. Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
CA2723842A1 (en) * 2008-05-09 2009-11-12 Peter Vanlandschoot Amino acid sequences directed against integrins and uses thereof
KR20180086297A (ko) * 2010-06-18 2018-07-30 엑스바이오테크, 인크. 관절염 치료
CA2864539C (en) 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
US11312775B2 (en) 2017-07-20 2022-04-26 University Of Virginia Patent Foundation Methods for treatment or prevention of a neurological immunity disorder

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) * 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
DE69230142T2 (de) * 1991-05-15 2000-03-09 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69309044T3 (de) 1992-01-13 2004-12-23 Biogen, Inc., Cambridge Behandlung von asthma
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
NZ262615A (en) 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
US6111598A (en) * 1993-11-12 2000-08-29 Peveo, Inc. System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CN1211123C (zh) 1994-01-25 2005-07-20 雅典娜神经科学公司 抗白细胞粘附分子vla－4的人源化抗体
EP0759302B1 (en) * 1994-04-26 2000-08-16 Kanebo Ltd. Remedy for rheumatoid arthritis
JPH08131185A (ja) * 1994-11-14 1996-05-28 Sumitomo Electric Ind Ltd マウスｖｌａ−１分子に対するモノクローナル抗体
JPH08160972A (ja) 1994-12-01 1996-06-21 Sega Enterp Ltd エフェクト制御方法、制御装置およびこれを利用したカラオケ装置
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9516399D0 (en) 1995-08-10 1995-10-11 Camelot Superabsorbents Ltd Process for the production of water-absorbing compositions
EP0859841B1 (en) * 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
AU718138B2 (en) 1995-08-29 2000-04-06 Kyowa Hakko Kirin Co., Ltd. Chimeric animal and method for constructing the same
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
FR2745912B1 (fr) * 1996-03-08 1998-05-29 Lorraine Laminage Procede et dispositif de controle de la soudabilite de toles sandwich
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
WO1999061040A2 (en) 1998-05-22 1999-12-02 Boys Town National Research Hospital USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE
DE19831710A1 (de) * 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
JP2003513005A (ja) 1998-10-06 2003-04-08 バイオジェン インコーポレイテッド α１β１インテグリンＩ−ドメインの結晶およびそれらの使用
JP5483515B2 (ja) * 1999-04-22 2014-05-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法
EA011384B1 (ru) * 1999-06-01 2009-02-27 Байоджен Айдек Ма Инк. Способ лечения воспалительного заболевания
US7601125B1 (en) 1999-06-17 2009-10-13 Desinger Kai Surgical, grooved director for collecting tissue in a minimally invasive manner
AU4259901A (en) 2000-03-28 2001-10-08 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
YU80903A (sh) 2001-04-13 2006-05-25 Biogen Inc. Antitela vla-1
AU2003215298A1 (en) 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
EP1546203B1 (en) 2002-08-01 2012-06-20 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
WO2005019177A1 (en) 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
US10119979B2 (en) 2006-05-25 2018-11-06 Biogen Ma Inc. Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
JP4951596B2 (ja) 2008-07-31 2012-06-13 株式会社日立製作所 冷却システム及び電子装置
EP2403874A1 (en) 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
KR101989628B1 (ko) 2009-12-21 2019-06-14 제넨테크, 인크. 항체 제제
AU2012212194B2 (en) 2011-02-03 2017-05-04 Santarus, Inc. Selection and treatment of subjects
WO2013105161A1 (ja) 2012-01-11 2013-07-18 パナソニック株式会社 圧接型半導体装置及びその製造方法
CA2864539C (en) 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations

Also Published As

Publication number Publication date
EP1488806B1 (en) 2015-12-09
CA2375827C (en) 2017-01-10
AU783989B2 (en) 2006-01-12
EP2314315A1 (en) 2011-04-27
NO20015864D0 (no) 2001-11-30
AU2006201540A1 (en) 2006-05-11
JP5960762B2 (ja) 2016-08-02
US9902774B2 (en) 2018-02-27
SI1488806T1 (sl) 2016-02-29
BG106226A (en) 2002-08-30
JP4817503B2 (ja) 2011-11-16
JP2004500328A (ja) 2004-01-08
US8557240B2 (en) 2013-10-15
GEP20063774B (en) 2006-03-27
PT1488806E (pt) 2016-02-26
CZ300710B6 (cs) 2009-07-22
HK1043320A1 (zh) 2002-09-13
YU85501A (sh) 2004-07-15
EP1488806A2 (en) 2004-12-22
HK1154352A1 (en) 2012-04-20
BG65579B1 (bg) 2009-01-30
US20140154259A1 (en) 2014-06-05
AU5724800A (en) 2000-12-18
JP2011157403A (ja) 2011-08-18
ES2557768T3 (es) 2016-01-28
US8084031B2 (en) 2011-12-27
SK17232001A3 (sk) 2002-09-10
EP2314315B1 (en) 2015-01-21
EA200400930A1 (ru) 2004-12-30
JP5623335B2 (ja) 2014-11-12
US20020146417A1 (en) 2002-10-10
JP2012176983A (ja) 2012-09-13
TR200103432T2 (tr) 2002-10-21
CA2375827A1 (en) 2000-12-07
DK1488806T3 (da) 2016-02-08
HUP0202568A2 (hu) 2002-11-28
EP1181054A1 (en) 2002-02-27
EE200100651A (et) 2003-02-17
NO20015864L (no) 2002-02-01
PT2314315E (pt) 2015-03-17
US20090324598A1 (en) 2009-12-31
IL146508A0 (en) 2002-07-25
US7462353B2 (en) 2008-12-09
NZ515686A (en) 2005-01-28
CZ20014249A3 (cs) 2002-06-12
ES2529706T3 (es) 2015-02-24
SI2314315T1 (sl) 2015-04-30
EA011384B1 (ru) 2009-02-27
US20120087925A1 (en) 2012-04-12
IL146508A (en) 2007-08-19
JP2007277253A (ja) 2007-10-25
BR0011250A (pt) 2002-03-05
US6955810B2 (en) 2005-10-18
CN1309419C (zh) 2007-04-11
MXPA01012388A (es) 2002-07-30
WO2000072881A1 (en) 2000-12-07
JP2016121184A (ja) 2016-07-07
EP1488806A3 (en) 2011-03-30
HUP0202568A3 (en) 2009-11-30
CY1116042T1 (el) 2017-01-25
JP2014210818A (ja) 2014-11-13
CN1390137A (zh) 2003-01-08
US20050226877A1 (en) 2005-10-13
IS6179A (is) 2001-11-28

Similar Documents

Publication Publication Date Title
US8084031B2 (en) Method for the treatment of inflammatory disorders
AU2002258778C1 (en) Antibodies to VLA-1
ZA200308568B (en) Antibodies to VLA-1.